Trials / Completed
CompletedNCT03963518
Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)
Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 631 (actual)
- Sponsor
- Institut Bergonié · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigate
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nivolumab monotherapy | nivolumab monotherapy |
| DRUG | nivolumab plus ipilimumab | nivolumab plus ipilimumab |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2019-05-24
- Last updated
- 2025-10-06
- Results posted
- 2025-09-15
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03963518. Inclusion in this directory is not an endorsement.